We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+18.77%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.81B
AUM Growth
+$81.2M
Cap. Flow
-$585M
Cap. Flow %
-10.08%
Top 10 Hldgs %
85.45%
Holding
128
New
20
Increased
23
Reduced
35
Closed
17

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.13M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.85M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.62M
4
PRQR icon
ProQR Therapeutics
PRQR
+$5.19M
5
ARRY
Array Biopharma Inc
ARRY
+$5.11M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$15M
3
ONC
BeOne Medicines Ltd
ONC
+$13M
4
BLUE
bluebird bio
BLUE
+$12.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.79%
2 Consumer Discretionary 22.09%
3 Healthcare 21.32%
4 Financials 0%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
76
Larimar Therapeutics
LRMR
$444M
$3.52M 0.06%
83,333
– –
SIOX
77
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.44M 0.06%
62,500
+40,625
+186% +$6.85M
BCRX icon
78
BioCryst Pharmaceuticals
BCRX
$2.51B
$3.41M 0.06%
650,000
-200,000
-24% -$1.02M
TSRO
79
CALL
DELISTED
TESARO, Inc.
TSRO
$3.23M 0.06%
25,000
-210,000
-89% -$26.1M
DVAX
80
DELISTED
Dynavax Technologies
DVAX
$3.23M 0.06%
+150,000
New +$2.37M
JNCE
81
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.12M 0.05%
200,000
-50,000
-20% -$707K
CLLS
82
Cellectis
CLLS
$320M
$2.85M 0.05%
100,000
– –
CBIO
83
Crescent Biopharma
CBIO
$618M
$2.83M 0.05%
2,025
– –
STML
84
DELISTED
Stemline Therapeutics, Inc.
STML
$2.77M 0.05%
250,000
– –
CALA
85
DELISTED
Calithera Biosciences, Inc
CALA
$2.76M 0.05%
8,750
-1,250
-13% -$394K
KYNB
86
Kyntra Bio
KYNB
$28.5M
$2.69M 0.05%
+2,000
New +$2.11M
RARE icon
87
Ultragenyx Pharmaceutical
RARE
$2.6B
$2.66M 0.05%
50,000
– –
CMRX
88
DELISTED
Chimerix, Inc.
CMRX
$2.63M 0.05%
500,000
– –
BLCM
89
CALL
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.31M 0.04%
+20,000
New +$2.1M
XNCR icon
90
Xencor
XNCR
$1.71B
$2.29M 0.04%
+100,000
New +$2.22M
KDNY
91
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.13M 0.04%
40,000
+20,000
+100% +$1.19M
FPRX
92
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.05M 0.04%
50,000
-100,000
-67% -$3.14M
LUMO
93
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$2.04M 0.04%
+22,222
New +$1.7M
CLDX icon
94
Celldex Therapeutics
CLDX
$3.35B
$1.93M 0.03%
45,000
– –
NERV icon
95
Minerva Neurosciences
NERV
$187M
$1.91M 0.03%
31,413
– –
BHVN
96
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.87M 0.03%
+50,000
New +$1.52M
NVLN
97
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$1.8M 0.03%
256,400
– –
SNDX icon
98
Syndax Pharmaceuticals
SNDX
$1.7B
$1.79M 0.03%
152,920
-147,080
-49% -$1.8M
LUMO
99
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.53M 0.03%
+16,667
New +$1.28M
KURA icon
100
Kura Oncology
KURA
$896M
$1.5M 0.03%
+100,000
New +$939K
2 3
4
5 6

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q3 2017 Portfolio in Review

As of Q3 2017, Artal Group held 128 positions worth $5.81B, up 1.4% from $5.72B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group withdrew a net $585M in Q3 2017, closing 17 positions and reducing 35 holdings. Its most notable exit was Goldman Sachs, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Artal Group opened a new position in Achillion Pharmaceuticals worth $4.49M.

  • Artal Group's largest Q3 2017 buy was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M.
  • Artal Group added most to Clovis Oncology, Inc. in Q3 2017, an estimated $7.13M increase.
  • Artal Group's biggest Q3 2017 reduction was Agios Pharmaceuticals, cutting an estimated $15M.
  • Artal Group fully exited Goldman Sachs in Q3 2017, selling an estimated $22.6M.
  • Artal Group's ten largest holdings make up 85% of its $5.81B portfolio in Q3 2017.
  • Artal Group opened 20 new positions and closed 17 in Q3 2017.
  • Artal Group's portfolio value rose 1.4% quarter-over-quarter to $5.81B.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.